Recently, Johnson et al.43 showed that HLA class II-positive tumours associated with CD4+ and CD8+ tumour infiltrate therapeutic response and improved survival in anti-PD-1-treated melanoma patients. The gene discussed is CD8A; the disease is melanoma.